Matthew Gardella explains why "fallen angel" reverse mergers have become an attractive alternative to the traditional IPO for privately held life sciences companies looking to go public.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
